<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03089333</url>
  </required_header>
  <id_info>
    <org_study_id>2016004830</org_study_id>
    <nct_id>NCT03089333</nct_id>
  </id_info>
  <brief_title>Effects of SGLT2 Inhibitor on Hemodynamic Parameters in Resistant Hypertensive Subjects</brief_title>
  <official_title>Effects of Dapagliflozin, an SGLT2 Inhibitor, on Hemodynamic Parameters, Target Organ Damage and Obesity Profile in Resistant Hypertensive Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Campinas, Brazil</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundação de Amparo à Pesquisa do Estado de São Paulo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Campinas, Brazil</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      New strategies trying to achieve blood pressure control and consequently reduce
      cardiovascular risk in resistant hypertensive subjects are promising. In this context, the
      SGLT2 inhibitor dapagliflozin, not yet investigated in resistant hypertension, arises as a
      potential drug in order to impact on blood pressure levels, as well as target organ damage
      and adiposity in this high-risk population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective: The investigators aim to assess whether the intervention with the SGLT2 inhibitor
      -dapaglifozin - reduces PA levels, target organ damage, fat profile and change the adipokines
      levels in patients with resistant hypertension with DM2. Methods and design: This crossover
      randomized, double-blind, interventional study controlled by standard therapy will include 20
      patients with resistant hypertension and type 2 diabetes, followed in Outpatient Clinic
      specialized in Resistant Hypertension at clinical Hospital-UNICAMP. They will be randomly
      assigned into two groups (1) initially treated with dapagliflozin in combination with their
      usual antihypertensive therapy and metformin, at 12 weeks (n = 10) or group (2) Control
      initially treated with glibenclamide at a dose of 5mg daily in combination with
      antihypertensive therapy usual and metformin, at 12 weeks (n = 10). Office ambulatory and
      home BP measurements; anthropometric measurements, determination of vascular stiffness by
      pulse wave velocity, echocardiogram, body bioimpedance, enzyme immunoassays for the
      determination of adipokines, and lab tests to evaluate biochemical parameters will be
      performed pre- and after the use of both treatments. Glycemic parameters, and weight will be
      assessed every 4 weeks. Results and conclusion: The use of SGLT2 inhibitor in these patients
      may provide new strategies for treatment of patients with resistant hypertension.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2016</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">October 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Two-way crossover design</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Systolic Blood Pressure</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Change in Office Systolic Blood Pressure after 12 weeks of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Ambulatory Systolic Blood Pressure</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Change in Ambulatory Systolic Blood Pressure after 12 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in weight</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Change in body weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in arterial stiffness</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Change in arterial stiffness measured by Sphygmocor device</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in left ventricular hypertrophy</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Change in left ventricular hypertrophy measured by Echocardiogram</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in microalbuminuria</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Change in microalbuminuria measured by Urine Albumin/Creatinine Ratio</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Hypertension</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Blood Pressure</condition>
  <condition>Obesity</condition>
  <condition>Cardiac Hypertrophy</condition>
  <condition>Microalbuminuria</condition>
  <condition>Vascular Stiffness</condition>
  <arm_group>
    <arm_group_label>Dapagliflozin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dapagliflozin 10mg daily for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glibenclamide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Glibenclamide 5mg daily for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin 10mg</intervention_name>
    <description>Dapagliflozin at a dose of 10mg daily in combination with metoformin and current antihypertensive therapy for 12 weeks</description>
    <arm_group_label>Dapagliflozin</arm_group_label>
    <arm_group_label>Glibenclamide</arm_group_label>
    <other_name>FARXIGA®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glibenclamide 5Mg Tablet</intervention_name>
    <description>Glibenclamide at a dose of 5mg daily in combination with metoformin and current antihypertensive therapy for 12 weeks</description>
    <arm_group_label>Dapagliflozin</arm_group_label>
    <arm_group_label>Glibenclamide</arm_group_label>
    <other_name>Glibenclamide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Resistant hypertension and type 2 diabetes diagnoses after a 6-month follow-up

          -  Use of metformin therapy

          -  Therapy adherence

          -  Agree to participate in the research protocol and sign the informed consent form

        Exclusion Criteria:

          -  secondary Hypertension

          -  pseudoresistance hypertension (poor medication adherence and white coat hypertension)

          -  patients with symptomatic ischemic heart disease, impaired renal function, liver
             disease and history of stroke, myocardial infarction and peripheral vascular diseases

          -  pregnancy

          -  smoking

          -  autoimmune diseases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rodrigo Modolo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Campinas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Campinas (UNICAMP)</name>
      <address>
        <city>Campinas</city>
        <state>São Paulo</state>
        <zip>13083970</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 20, 2017</study_first_submitted>
  <study_first_submitted_qc>March 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2017</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Campinas, Brazil</investigator_affiliation>
    <investigator_full_name>Rodrigo Modolo</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
    <mesh_term>Cardiomegaly</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glyburide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

